Is Grail (GRAL) Stock a Buy, Sell, or Hold at Under $70?
· finance.yahoo.com
The developer of blood-based cancer tests still has a bright future.
Grail (NASDAQ: GRAL), which was spun off from Illumina (NASDAQ: ILMN) in 2024, reached a record high of $116.06 on Jan. 22. But today, the cancer test developer...